

Marie Krogh Young Women in Science Prize

TERMS & CONDITIONS



The *Marie Krogh Young Women in Science Prize* ("Prize") is an initiative by Novo Nordisk Pharmaceuticals Pty Ltd ("Novo Nordisk") to recognise and support outstanding female-identifying scientists in Australia and New Zealand. The Prize aims to celebrate excellence in scientific research and inspire the next generation of women. Please read these Terms and Conditions carefully. Failure to meet any of the Terms and Conditions may result in disqualification. Novo Nordisk reserves the right to disqualify any non-compliant entries at its sole discretion, and no correspondence will be entered into in relation to such disqualification.

1. Definitions

For the purposes of these Terms and Conditions:

Applicable Laws means all laws, regulations, industry codes and regulatory requirements applicable in Australia and/or New Zealand, including privacy, taxation, advertising and data protections laws.

Canberra Events means the official Finalist activities held in Canberra, including the Parliament House reception and Prize announcement dinner as organised by Novo Nordisk.

Closing Date means the date on which Entries for the Prize will close or as otherwise notified by Novo Nordisk.

Eligible Jurisdictions means Australia and New Zealand.

Entrant means the individual who has submitted an Entry via the online entry platform by the Closing Date.

Entry means a submission of a completed application via the online entry platform that complies with the Terms and Conditions of the Prize.

Finalist means an Entrant selected by the Judging Panel as one of the top eight candidates, including seven (7) runner-up Entrants and one (1) Winner.

Judging Panel means the group of individuals appointed by Novo Nordisk to assess applications and determine the Finalists.

New Zealand means the sovereign state of New Zealand.

New Zealand Entrant means an Entrant who is a citizen or permanent resident of New Zealand and meets the jurisdiction-specific eligibility requirements set out in these Terms and Conditions.

New Zealand Paying Agent means Novo Nordisk Pharmaceuticals Limited (Company No. 481 264), a New Zealand affiliate entity that may be used to facilitate payment of Prize Money to New Zealand Finalists on behalf of Novo Nordisk.

Prize means the Marie Krogh Young Women in Science Prize, including all associated awards, recognition, and events organised by Novo Nordisk.

Prize Money means AUD \$50,000 to be received by the Winner and AUD \$5,000 to be received by each of the seven (7) remaining Finalists.

Marie Krogh Alumni means the alumni program established to foster long-term connection and collaboration among Finalists of the Prize.

Personal Data refers to any personal information collected for the Prize which can identify an individual, including name, contact details, career history, and personal statements.

Promotional Material means content related to the Prize, including materials related to the promotion of Prize, Finalists and Marie Krogh Alumni such as photographs, biographies, and media interviews for activities.

Submission Guidelines refers to the supplementary document provided to applicants outlining detailed instructions and expectations for preparing and submitting a valid Entry.

Winner refers to the Finalist selected by the Judging Panel to receive the primary Prize Money of AUD \$50,000.

2. Prize Money and Disbursement

- 2.1. Eight (8) Finalists will be selected. Of these:
 - (a) One (1) Winner will receive Prize Money of **AUD \$50,000**.
 - (b) Seven (7) runners-up Finalists will each receive Prize Money of **AUD \$5,000**.
- 2.2. Prize Money will be awarded to each Finalist as a single payment via bank transfer unless otherwise specified by Novo Nordisk.
All Prize Money will be paid in Australian dollars (AUD), including to New Zealand Finalists.
- 2.3. Prize Money will be awarded without restriction on use by the Finalists. However, Finalists are encouraged to use the funds in ways that advance their research, professional development, or the broader scientific community, including for the following purposes:
 - (a) Research project support
 - (b) Conference attendance
 - (c) Research assistant employment
 - (d) Equipment purchase
 - (e) Mentorship and outreach activities.
- 2.4. Prize Money will be paid by bank transfer to Finalists in accordance with instructions provided by each Finalist to Novo Nordisk, subject to confirmation of bank details and verified compliance with eligibility requirements. Where a Finalist is based in New Zealand, Prize Money may be paid by or through the New Zealand Paying Agent on behalf of Novo Nordisk. Any currency conversion costs associated with the receipt of AUD payments by New Zealand Finalists are the sole responsibility of the Finalist.
- 2.5. The Prize is administered by Novo Nordisk Pharmaceuticals Pty Ltd (ABN 40 002 879 996). Where Prize Money is payable to New Zealand Finalists, Novo Nordisk may arrange for payment to be made by or through Novo Nordisk Pharmaceuticals Limited (Company No. 481 264), a New Zealand affiliate entity acting as paying agent on its behalf.

3. Eligibility Criteria

- 3.1. To be eligible to apply for the Marie Krogh Young Women in Science Prize, Entrants must meet all of the following criteria as at the Closing Date:
 - (a) Be either:
 - (i) an Australian citizen or permanent resident; or
 - (ii) a New Zealand citizen or permanent resident, who identifies as female.
 - (b) Be professionally engaged in one or more of the following fields:
 - (i) Scientific research, including biomedical, health, clinical, or life sciences;
 - (ii) Medical or clinical practice; or
 - (iii) Pharmaceutical research or development.
 - (c) Be currently based in Australia or New Zealand, or have made significant contributions to science, healthcare, or public health in Australia or New Zealand.
 - (d) Be at an early-to-mid career stage, typically defined as within ten (10) years of conferral of highest degree (PhD, MD, or equivalent). Consideration will be given to applicants whose careers have been

interrupted or who have followed non-linear pathways, including career changes, parental leave, or other significant personal or professional circumstances.

- (e) Have no substantiated findings of professional or academic misconduct or breaches of relevant ethical principles or guidelines.
- (f) Be available and willing to attend the Canberra Events on 13 October 2026, including the Finalist Reception, Prize announcement dinner and Alumni Breakfast on 14 October 2026. Novo Nordisk will cover reasonable travel and accommodation expenses as outlined in Section 7 of these Terms and Conditions.

- 3.2. Eligibility requirements may differ slightly by jurisdiction. Entrants must ensure they meet the eligibility requirements applicable to their country of citizenship and/or residence at the time of Entry. Novo Nordisk reserves the right to apply jurisdiction-specific checks prior to Finalist confirmation.

4. Entries

- 4.1. Submission of an application by an Entrant constitutes acceptance of these Terms and Conditions.
- 4.2. Entries must be submitted via the online entry application platform by the Closing Date. Late or incomplete submissions will not be accepted.
- 4.3. Novo Nordisk is not responsible for Entries that are delayed, incomplete, or are lost or not received due to technical issues.
- 4.4. Entrants are responsible for ensuring that all information provided is accurate, complete, and truthful. Novo Nordisk reserves the right to disqualify any Prize submission that violates these Terms and Conditions, relevant ethical principles or guidelines or fails to meet the Eligibility Criteria in Section 3 of these Terms and Conditions. Any misrepresentation, plagiarism, fabrication of information or any other forms of academic or professional misconduct may result in disqualification.
- 4.5. Entrants must include all required materials as specified in the application form.
- 4.6. Entrants consent to the use of their name, likeness, and biographical information by Novo Nordisk for promotional and media purposes related to the Prize. Finalists may be asked to provide additional Promotional Materials, such as a photograph or biography.
- 4.7. An Entrant is responsible for keeping a copy of their own Entry if they wish to do so. Entries will not be returned to the Entrants.
- 4.8. In relation to any Entry, Novo Nordisk may request clarification or additional information. Additional information to the Entry may not be accepted if provided after the Closing Date.
- 4.9. Entrants agree and acknowledge that they are not aware of any conflict of interest related to the Prize or submission of Entry. Entrants must inform Novo Nordisk via email at MKprize@novonordisk.com of any such conflict of interest including, but not limited to, affiliations with other pharmaceutical companies.

5. Selection Process

- 5.1. All Entries will be reviewed internally by Novo Nordisk for eligibility and pre-assessment in accordance with the judging approach set out in the Submission Guidelines. Based on eligibility checks and internal pre-assessment, selected Entries will be reviewed by the Judging Panel for selection of Finalists.
- 5.2. All Finalists and the Winner will be chosen by a Judging Panel composed of eminent figures from academia, industry, and government in Australia and/or New Zealand. The decisions and deliberations of the Judging Panel will remain confidential. All decisions of the Judging Panel are final, and no correspondence will be entered into.
- 5.3. Selection will be based on:
 - (a) Innovation in Scientific Research
 - (b) Impact on Healthcare
 - (c) Leadership and Community Engagement.
- 5.4. Entrants are encouraged to refer to the Submission Guidelines document when preparing their application. This document provides detailed guidance on how to address the selection criteria and present a competitive submission.
- 5.5. Novo Nordisk will take reasonable steps to ensure that the judging process is equitable across jurisdictions, including consideration of differing research environments and career contexts in Australia and New Zealand. This may include inclusion of relevant jurisdictional expertise on the Judging Panel.

- 5.6. All members of the Judging Panel are required to declare any actual or perceived conflicts of interest prior to and during the judging process. Where a conflict of interest is identified, Novo Nordisk will take appropriate steps to manage or mitigate that conflict, which may include the recusal of the relevant panel member from assessment of specific Entries. All Judging Panel members are bound by confidentiality obligations in respect of all applications, deliberations and outcomes.

6. Finalists

- 6.1. Finalists will be notified in writing by use of the contact email provided in the Entry by the end of September 2026 and publicly announced shortly thereafter.
- 6.2. The Winner will be announced at a formal dinner event in Canberra on 13 October 2026.
- 6.3. Finalists may be requested by Novo Nordisk to provide images and a short film and other Promotional Material relating to their Entry.
- 6.4. By submitting an Entry, Finalists grant permission to Novo Nordisk to use information related to the Finalists, including:
- (a) name and title;
 - (b) image/s;
 - (c) information provided in the Entry;
 - (d) any audio or video recording of the Finalist; and
 - (e) statements made by the Finalist,

(information) in relation to the Prize for the following purposes:

- (i) Novo Nordisk's internal purposes, which may include sharing information with Novo Nordisk employees at meetings or incorporating information for activities related to the Prize;
 - (ii) Novo Nordisk external business purposes, including promotional activities in the public domain on social media platforms, websites and other media channels;
 - (iii) to be incorporated in Promotional Materials that are created by or on behalf of Novo Nordisk by third parties.
- 6.5. Finalists agree that Novo Nordisk may edit information, including Promotional Material as long as Novo Nordisk does not misrepresent the individual or change the meaning of the statements made by individuals. Novo Nordisk will use its best efforts to ensure that any modifications to the information or Promotional Materials do not undermine the accuracy or integrity of the information.
- 6.6. Finalists release Novo Nordisk and its officers, employees and agents from any claim or liability in connection with the information, except for any liability which cannot be excluded by law. To the extent that any third-party content is used in the Promotional Material, it is the sole responsibility of the Entrant to secure permission for the use of the third-party content, including the right to sublicense for use by the Novo Nordisk in accordance with these Terms and Conditions. Entrants indemnify Novo Nordisk against any claims for infringement of third-party intellectual property rights.

7. Canberra Event Attendance

- 7.1. All eight (8) Finalists are required to attend the following Canberra Events:
- (a) Finalist Reception activities at Parliament House or Government House on 13 October 2026.
 - (b) The award announcement dinner in the evening of 13 October 2026
 - (c) Alumni Breakfast the morning of 14 October 2026.
- 7.2. Novo Nordisk will cover reasonable domestic or trans-Tasman economy travel and accommodation costs for each Finalist to attend the Canberra Events subject to compliance with Novo Nordisk travel policies, including:
- (a) Return economy airfares or equivalent transportation;
 - (b) One night's accommodation (two nights if required due to travel times);
 - (c) Ground transfers to/from the airport and Canberra Event venues.
- 7.3. Travel insurance is the responsibility of the Finalists.

- 7.4. If a Finalist is unable to attend the required events, they may become ineligible to receive the Prize, and the opportunity may be extended to the next highest-ranked eligible Entrant, as determined by the Judging Panel.
- 7.5. New Zealand Finalists are responsible for ensuring they meet any applicable entry or travel requirements to Australia. Where attendance is impacted by visa, border or exceptional circumstances, Novo Nordisk may, at its discretion, permit remote participation without prejudice to eligibility.

8. Costs and Expenses

- 8.1. There is no fee to submit an Entry for the Prize.
- 8.2. Entrants enter the Prize at their own risk and Novo Nordisk, and its affiliates, partners or supporters are not liable for any loss, damage, or expenses incurred by Entrants in connection with the preparation, submission, or follow-up of their Entry.

9. Publicity and Media

- 9.1. By submitting an Entry, Entrants warrant they will not promote, endorse or advertise Novo Nordisk products to the public, including on social media or other platforms.
- 9.2. Promotion, endorsement or advertising of Novo Nordisk products to the public is considered a material breach of these Terms and Conditions and Novo Nordisk reserves the right to disqualify the Entrant from the Prize.
- 9.3. Finalists agree to participate in events, media and communication activities, including interviews and photographs, in their capacity as Winner or Finalist. Such events and activities may be filmed and streamed in various media. By attending the event and activity, Finalists consent to being filmed for such purpose, unless they otherwise notify Novo Nordisk in writing.
- 9.4. Finalists may be notified prior to the release of any media statements or public announcements.
- 9.5. Finalists and Winners may publicise that they are a:
 - (a) Novo Nordisk Marie Krogh Prize Winner; and / or
 - (b) Novo Nordisk Marie Krogh Prize Finalist,
 in each case, the reference must include the full Prize name and year
 (For example: *Winner of the 2026 Novo Nordisk Marie Krogh Young Women in Science Prize*)
- 9.6. Each Finalist may be provided with Prize specific Promotional Material to promote their Finalist and/or Winner status which can be used at their discretion (including for email signatures, personal webpages, blogs, portfolios, etc.) Additional terms and conditions may apply to the use of the digital badge. For the avoidance of doubt, where Finalists belong to, or are affiliated with, organisations, those organisations are not permitted to use the digital badge to promote their organisation.
- 9.7. Entrants agree not to use the name or trademarks of Novo Nordisk in a manner that may impact the reputation or goodwill of Novo Nordisk or the Prize.

10. Confidentiality and Intellectual Property

- 10.1. All applications and supporting materials will be treated as confidential
- 10.2. Intellectual property submitted with an Entry remains the sole ownership of the Entrant.
- 10.3. Submission of an application does not imply any transfer of intellectual property rights to Novo Nordisk. Nothing in the Terms and Conditions affects the ownership of any intellectual property rights of the Entrant which came into existence before submission of an Entry.
- 10.4. Novo Nordisk may provide Finalists with materials or information in connection with the Prize. If any of the material provided to the Finalist by Novo Nordisk is confidential in nature, Novo Nordisk will identify that material or information as such, and the Finalist agrees to keep that information confidential.
- 10.5. Finalists must agree to take all reasonable steps to ensure that any confidential information is not disclosed to any unauthorised person.

11. Taxation and Financial Disclosure

- 11.1. Prize Money is provided without any obligation on the part of Novo Nordisk to determine its tax or other financial treatment. Novo Nordisk accepts no liability for any tax or other financial consequences that may arise from the receipt or use of the Prize Money.
- 11.2. Novo Nordisk makes no representation or warranties as to whether the payment is assessable income or otherwise taxable in the hands of the Prize Money recipient.
- 11.3. Prize Money recipients are solely responsible for assessing and complying with any applicable taxation obligations including but not limited to income tax.
- 11.4. Novo Nordisk strongly recommends that the Prize Money recipient seek independent financial and/or tax advice to determine specific individual obligations.
- 11.5. Prize Money awarded to New Zealand Finalists will be paid in AUD by Novo Nordisk Pharmaceuticals Pty Ltd (ABN 40 002 879 996) or, where applicable, through the New Zealand Paying Agent, Novo Nordisk Pharmaceuticals Limited (Company No. 481 264). Such payments may be subject to tax, withholding, reporting, or obligations under New Zealand law. Novo Nordisk reserves the right to withhold or deduct any amounts required by applicable law. Novo Nordisk makes no representation as to the tax treatment of Prize Money under New Zealand law and accepts no responsibility for any resulting obligations arising for participants. New Zealand Finalists are solely responsible for complying with all applicable New Zealand tax and financial reporting requirements and are strongly encouraged to seek independent New Zealand tax advice prior to accepting Prize Money.

12. Compliance

- 12.1. This Prize operates in accordance with these Terms and Conditions, and in compliance with applicable laws and Novo Nordisk policies as amended from time-to-time.
- 12.2. This Prize is not a game of chance or trade promotion lottery.
- 12.3. Novo Nordisk will nominate an internal owner responsible for oversight of jurisdiction-specific eligibility, compliance and communications relating to New Zealand participation.

13. Withdrawal or Forfeiture

- 13.1. Novo Nordisk reserves the right to take appropriate actions to:
 - (a) Withhold or cancel Prize distribution in cases of misconduct, misrepresentation, or breaches of these Terms and Conditions.
 - (b) Revoke the award of Prize Money if new information emerges that materially affects a Finalist's eligibility or the integrity of the Prize.

14. Reporting and Impact Tracking

- 14.1. In support of long-term program evaluation, the winner of the Prize is encouraged to submit a written impact statement within 12 months of receiving the Prize Money. This statement could include:
 - (a) professional achievements or milestones reached as a result of the award of the Prize;
 - (b) broader impacts on the recipient's research, collaboration, or community engagement.

15. Marie Krogh Alumni

- 15.1. All Finalists of the Marie Krogh Young Women in Science Prize will be included in the inaugural cohort of the Marie Krogh Alumni program (MKA). The MKA is designed to foster long-term connection, collaboration, and support among outstanding women in science. Finalists may opt out of the MKA at any time by notifying Novo Nordisk in writing at MKPrize@novonordisk.com.

16. Diversity and Equity

- 16.1. This Prize is dedicated to supporting women in science. Novo Nordisk is committed to fostering an inclusive environment and encourages applications from individuals of all backgrounds, including those from underrepresented communities. All Entries will be assessed equitably and without bias.

- 16.2. Equity across participating jurisdictions is a core principle of the Prize. Applications from Australia and New Zealand will be assessed using consistent criteria, applied in a manner that recognises jurisdictional context and opportunity.

17. Feedback and Dispute Resolution

- 17.1. To ensure the integrity and fairness of the judging process, feedback will not be provided to Entrants at any stage of the selection process.
- 17.2. No correspondence will be entered into regarding the outcome of applications. Any feedback or complaints correspondence can be provided by contacting MKprize@novonordisk.com.

18. Data Privacy and Consent

- 18.1. Novo Nordisk collects, stores and handles information in accordance with applicable privacy laws in Australia and New Zealand, including the *Australian Privacy Act 1988 (Cth)* and the *New Zealand Privacy Act 2020*. Personal data may be transferred between Australia and New Zealand for the purposes of administering the Prize. A copy of Novo Nordisk's Privacy Policy can be found at: <https://www.novonordisk.com.au/privacy-policy.html>.
- 18.2. By submitting an application, Entrants consent to the collection, use, and storage of their personal data for the purposes of administering the Prize. Information collected for the Prize includes, but is not limited to, information such as name, contact details, career history, and personal statements.
- 18.3. By submitting an Entry, Entrants expressly consent to the cross-border transfer of their personal data between Australia and New Zealand and acknowledge that such transfers are necessary for Prize administration, judging, communication and reporting.
- 18.4. New Zealand Entrants acknowledge that their personal data will be transferred to and processed in Australia by Novo Nordisk Pharmaceuticals Pty Ltd (ABN 40 002 879 996) for the purposes of administering the Prize. This transfer is made with the express consent of the Entrant as provided in these Terms and Conditions, in accordance with the New Zealand Privacy Act 2020. Where the New Zealand Paying Agent is involved in Prize administration or payment, personal data may also be shared with Novo Nordisk Pharmaceuticals Limited (Company No. 481 264) for those purposes.

19. Jurisdictional Communications

- 19.1. All public-facing communications relating to the Prize will be reviewed to ensure neutrality and relevance across Australia and New Zealand.
- 19.2. Novo Nordisk may issue jurisdiction-specific guidance, FAQs or clarification to support Entrants' understanding of eligibility and participation requirements.

20. Disclaimers

- 20.1. Novo Nordisk reserves the right to:
- (a) Amend the terms of the Prize, including eligibility criteria, Submission Guidelines, timelines, or award structure, at its sole discretion.
 - (b) Cancel, suspend, or modify the Prize at any time without prior notice, where necessary due to unforeseen circumstances or events beyond its control.

21. Governing Law

- 21.1. These Terms and Conditions are governed by the laws of New South Wales, Australia. Each party submits to the non-exclusive jurisdiction of the courts of New South Wales for the resolution of any dispute arising in connection with the Prize.